Related Experiment Video
Updated: Feb 8, 2026
Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
Cardiovascular Risk Assessment in Patients with Hypertriglyceridemia
Matthew C Evans1, Tapati Stalam1, Michael Miller2
1Department of Medicine, Cardiovascular Medicine Division, University of Maryland School of Medicine, 110 S Paca St., Suite 7-124, Baltimore, MD, 21201, USA.
Hypertriglyceridemia poses significant cardiovascular risk, even with optimized cholesterol levels. Ongoing research explores treatments like pemafibrate and omega-3 fatty acids to manage this residual risk.
Area of Science:
- Cardiology
- Metabolic Disorders
- Pharmacology
Background:
- Cardiovascular risk assessment in hypertriglyceridemia is complex due to comorbidities like hypertension and diabetes.
- Residual cardiovascular risk persists despite aggressive management of low-density-lipoprotein cholesterol (LDL-C).
Purpose of the Study:
- To quantify the cardiovascular risk associated with hypertriglyceridemia.
- To review meta-analyses and subgroup analyses of trials on hyperlipidemia treatment.
Main Methods:
- Examination of meta-analyses.
- Subgroup analyses of major randomized controlled trials focused on hyperlipidemia treatment.
Main Results:
- Recent trials with PCSK9 inhibitors show substantial residual cardiovascular risk despite significant LDL-C reduction.
- Optimization of LDL-C with statins, PCSK9 inhibitors, ezetimibe, bile acid sequestrants, and niacin does not eliminate residual risk.
Conclusions:
- Hypertriglyceridemia remains a significant contributor to residual cardiovascular risk.
- Ongoing trials investigating pemafibrate and omega-3 fatty acids are crucial for managing hypertriglyceridemia and its associated cardiovascular outcomes.
More Related Videos
10:11Fundus Photography as a Convenient Tool to Study Microvascular Responses to Cardiovascular Disease Risk Factors in Epidemiological Studies
Published on: October 22, 2014
19:15Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Related Concept Videos
01:29Assessment of the Cardiovascular System II: Inspection
Head and Neck
01:25Assessment of the Cardiovascular System IV: Auscultation
Normal Heart Sounds
S1 (First Heart Sound)-
S1 is made by the closure of the mitral and tricuspid valves (atrioventricular valves), marking the beginning of systole.
S2 (Second Heart Sound)-
S2 is made by the closure of the aortic and pulmonic valves (semilunar valves), marking the end of the systole.
01:23Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
01:27Assessment of the Cardiovascular System III: Palpation
Jugular Venous Pressure (JVP) Measurement
Position the patient at a thirty- to forty-five-degree angle or in a semi-fowler's position. Look for the highest point of pulsation in the internal jugular vein and measure the vertical distance to the angle of Loius or sternal angle. A normal JVP is 3-4 cm above...
01:17Design Example: Analyzing Capacity Contours for Flood Risk Assessment
01:12Relative Risk